Nutra Pharma Announces TCN's Full Launch of Their Nyloxin(R) Distribution Model
October 08 2013 - 8:30AM
Marketwired
Nutra Pharma Announces TCN's Full Launch of Their Nyloxin(R)
Distribution Model
Nutra Pharma Is Announcing the Launch of TCNs Global Marketing
and Distribution Campaign for Nutra Pharma's Over-the-Counter (OTC)
Pain Reliever, Nyloxin(R)
CORAL SPRINGS, FL--(Marketwired - Oct 8, 2013) - Nutra Pharma
Corp. (OTCQB: NPHC), a biotechnology company that is developing
treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple
Sclerosis (MS), is providing updates on the sales and marketing
activities of TCN, a distributor of Nutra Pharma's over-the-counter
(OTC) pain reliever, Nyloxin®.
In September 2012, Nutra Pharma announced the beginning of
distribution efforts by the TCN group of direct distributors. Since
that time, TCN has worked diligently to introduce Nyloxin® to
approximately 40,000 distributors in the United States and almost
400,000 distributors globally. In August 2013, TCN re-launched
their company as the "True Cash Network" and have
subsequently expanded their internet presence. They have been
working to overhaul their product offerings and have allowed their
distributors personal websites under their http://www.MyNyloxin.com
portal. Additionally, TCN has scheduled marketing efforts in the US
that will include internet, radio and television.
"The Nyloxin products continue to represent a wonderful
opportunity for our distributors," commented Dalton Johnson, CEO of
TCN. "These are pain-relievers and anti-inflammatory drugs that
have provided great results with almost no risk of side effects. We
are now in the process of merging our databases that will
eventually double our distributor outreach with the goal to achieve
significant sales through our distributors that will provide
continuity as they use and order the product every month," he
concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin®
is currently available in the United States as an oral spray for
treating back pain, neck aches, headaches, joint pain, migraines,
and neuralgia, and as a topical gel for treating joint pain, neck
pain, arthritis pain, and pain from repetitive stress. In addition
to its everyday strength formulation, Nyloxin® is also offered in
an extra strength formula for more advanced, Stage 3, chronic
pain.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
Additionally, the Company markets several drug products for sale
for the treatment of pain under the brands Cobroxin® and Nyloxin™.
For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or http://www.Nyloxin.com.
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The sales efforts of TCN should not
be construed as an indication in any way whatsoever of the future
value of the Company's common stock or its financial value. The
Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Apr 2023 to Apr 2024